iRadimed Corporation (IRMD) Earning Somewhat Favorable Press Coverage, Analysis Finds
News articles about iRadimed Corporation (NASDAQ:IRMD) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. iRadimed Corporation earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the medical equipment provider an impact score of 46.5387715222681 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
iRadimed Corporation (NASDAQ:IRMD) opened at $13.60 on Tuesday. The stock has a market capitalization of $145.13, a price-to-earnings ratio of 105.77 and a beta of 1.67. iRadimed Corporation has a twelve month low of $7.85 and a twelve month high of $15.00.
iRadimed Corporation (NASDAQ:IRMD) last posted its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.35. The business had revenue of $5.69 million during the quarter, compared to the consensus estimate of $5.60 million. iRadimed Corporation had a return on equity of 4.58% and a net margin of 6.51%. The firm’s quarterly revenue was down 25.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.14 earnings per share. equities analysts expect that iRadimed Corporation will post 0.05 earnings per share for the current fiscal year.
IRMD has been the subject of a number of research analyst reports. Zacks Investment Research raised iRadimed Corporation from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research note on Friday, August 4th. Roth Capital raised iRadimed Corporation from a “neutral” rating to a “buy” rating and raised their price target for the stock from $9.00 to $12.00 in a research note on Monday, July 31st. Finally, ValuEngine raised iRadimed Corporation from a “sell” rating to a “hold” rating in a research note on Friday, October 6th.
ILLEGAL ACTIVITY WARNING: This piece was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.watchlistnews.com/iradimed-corporation-irmd-earning-somewhat-favorable-press-coverage-analysis-finds/1701456.html.
iRadimed Corporation Company Profile
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.
Receive News & Ratings for iRadimed Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.